ReviewCell biology and toxicology2026
Mycotoxins, gut microbiota alterations and liver disease in animals: A scoping review.
Review in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Black Soldier Fly Larvae Bioconvert Deoxynivalenol-Contaminated Feed Without Toxin Accumulation: Growth Performance, Residue Distribution, and Gut Microbiota Responses.Microorganisms · 2026Article
- Ferulic Acid Alleviates the Hepatotoxicity of Aflatoxin B1 on Broilers by Conjugating and Down-Regulating Chicken CYP1A5 and CYP2W1.Veterinary sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycotoxins are fungal secondary metabolites widely detected in up to eighty percent of frequently consumed foods, strongly associated with toxicological mechanisms. Evidence indicates that hepatic pathophysiology entails gut microbiota dysbiosis mediated by the complex, bidirectional interactions within the gut-liver axis. This scoping review aims to provide insight into the relationship between mycotoxins, gut microbiota, and liver disease in animals, having been conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (n = 44). The analyzed species were hens, broilers, rabbits, mice, carps, turbots, Lateolabrax maculatus, chicks, sheep, and rats. The most altered liver parameters, as a consequence of mycotoxin exposure, were alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, malondialdehyde, reactive oxygen species, superoxide dismutase, glutathione peroxidase, tumor necrosis factor-α, lipopolysaccharide, and inflammatory infiltration. Gut microbiota changes were analyzed at phylum (Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Verrucomicrobia) and genus level (Bifidobacterium, Lactobacillus, Clostridium, Ruminococcus, Akkermansia, Escherichia, Allobaculum, Blautia, Staphylococcus, Prevotella, Bacteroides, Turicibacter, Corynebacterium, Roseburia, Coprococcus). What is more, out of more of 400 existing mycotoxins, only a small fraction of mycotoxins has been investigated in the interplay of the gut-liver axis ((Aflatoxin B1 (AFB1), ochratoxin A (OTA), deoxynivalenol (DON), zearalenone (ZEN), enniatins (ENNs) and T-2 toxin)). Therefore, more research is to better understand the interplay of interactions regarding mycotoxins and the gut microbiota-liver axis, focusing on the formulation of new functional foods and/or nutraceuticals as toxicity mitigating strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.